SLC6A
Genomenon Partners With Neurodevelopmental Disease Groups on Drug Development
The Ann Arbor, Michigan-based bioinformatics company will provide AI-driven genomic data analysis in search of precision treatments for several rare pediatric disorders.
The pharmacy benefits manager will study whether its members are more willing to take -- and stick with -- antidepressant and antipsychotic drugs prescribed to them based on a genetic test that suggests they are most likely to benefit from such treatment.
AssureRx has added a fifth gene, CYP1A2, to its GeneSightRx pharmacogenomic test to guide treatment decisions for psychiatric patients.